Skip to content
Targeted Oncology· @TargetedOnc · X·· 23 hours agoScore70

KEYNOTE-B49

Body · original

Could PD-L1 selection be the real story in KEYNOTE-B49?

In CPS ≥10, PFS HR was 0.59 (median 7.5 vs 4.4 months).

Is this a clinically meaningful subgroup or an exploratory signal?

We need interaction testing, subgroup OS and patient-reported outcomes. #ESMO26

64 views · 0 likes · 0 reposts · 0 replies

Conference abstracts
LBA51matched by Proffered paper 2: Breast cancer, early and advanced stage

Results from KEYNOTE-B49: A phase 3, randomized, double-blind study of pembrolizumab (pembro) vs placebo (pbo) plus chemotherapy (CT) in participants (pts) with HR+/HER2− advanced breast cancer (ABC)

https://esmocongress.esmo.org

Source: Targeted Oncology · x.com

CBACBA Frontier Insights (CFI)Chinese Biopharmaceutical Association (CBA)www.cba-usa.org